354 related articles for article (PubMed ID: 19322958)
1. Neuroprotection: a new strategy in the treatment of schizophrenia. Treatment of first-episode psychosis.
Buckley PF
CNS Spectr; 2007 Oct; 12(10 Suppl 18):7-10. PubMed ID: 19322958
[No Abstract] [Full Text] [Related]
2. Neuroprotection: a new strategy in the treatment of schizophrenia. Early detection and intervention.
Perkins DO
CNS Spectr; 2007 Oct; 12(10 Suppl 18):10-3. PubMed ID: 19322959
[No Abstract] [Full Text] [Related]
3. Drugs for psychotic disorders.
Treat Guidel Med Lett; 2010 Aug; 8(96):61-4; quiz two pages following last numbered page.. PubMed ID: 20651640
[No Abstract] [Full Text] [Related]
4. Rational pharmacotherapy in early psychosis.
Remington G
Br J Psychiatry Suppl; 2005 Aug; 48():s77-84. PubMed ID: 16055813
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of an early psychosis intervention program.
Pelosi AJ
Aust N Z J Psychiatry; 2005 Jun; 39(6):522-3; author reply 523-4, 525-6. PubMed ID: 15943656
[No Abstract] [Full Text] [Related]
6. Examining the effectiveness of antipsychotic medication in first-episode psychosis.
Taylor M; Cavanagh J; Hodgson R; Tiihonen J
J Psychopharmacol; 2012 May; 26(5 Suppl):27-32. PubMed ID: 22337711
[TBL] [Abstract][Full Text] [Related]
7. [Drug treatment of functional psychotic disorders].
Bridler R; Umbricht D; Hell D
Praxis (Bern 1994); 2001 May; 90(22):981-6. PubMed ID: 11450186
[TBL] [Abstract][Full Text] [Related]
8. Benefits of atypical antipsychotic medications in the treatment of psychosis.
White DL
Kans Nurse; 2003; 78(10):1-2. PubMed ID: 14746070
[No Abstract] [Full Text] [Related]
9. Risperidone treatment of febrile catatonia in first-episode psychosis.
Duggal HS
Gen Hosp Psychiatry; 2005; 27(1):80-1. PubMed ID: 15694223
[No Abstract] [Full Text] [Related]
10. The CATIE study and its implications for antipsychotic drug use.
Janicak PG
Essent Psychopharmacol; 2006; 7(1):53-63. PubMed ID: 16989293
[No Abstract] [Full Text] [Related]
11. Pharmacology and mechanism of action of existing and new neuroleptics.
Niemegeers CJ
Acta Psiquiatr Psicol Am Lat; 1990; 36(1-2):26-36. PubMed ID: 1981439
[No Abstract] [Full Text] [Related]
12. Metabolic disturbances associated with antipsychotic use.
Newcomer JW
J Clin Psychiatry; 2001; 62 Suppl 27():3-4; discussion 40-1. PubMed ID: 11806487
[No Abstract] [Full Text] [Related]
13. Neuroprotection: a new strategy in the treatment of schizophrenia. Neurobiological basis of neurodegeneration and neuroprotection.
Lieberman JA
CNS Spectr; 2007 Oct; 12(10 Suppl 18):4-6. PubMed ID: 17934388
[No Abstract] [Full Text] [Related]
14. Legal fallacies of antipsychotic drugs.
Erickson SK; Ciccone JR; Schwarzkopf SB; Lamberti JS; Vitacco MJ
J Am Acad Psychiatry Law; 2007; 35(2):235-46. PubMed ID: 17592170
[TBL] [Abstract][Full Text] [Related]
15. Is oestrogen neuroprotective?
Agius M; Hockings H; Wilson C; Lane D
Psychiatr Danub; 2009 Sep; 21 Suppl 1():120-7. PubMed ID: 19789496
[TBL] [Abstract][Full Text] [Related]
16. [Cognitive deficits in schizophrenia and other psychotic disorders].
Fagerlund B; Glenthøj BY
Ugeskr Laeger; 2008 Nov; 170(46):3770-2. PubMed ID: 19014728
[TBL] [Abstract][Full Text] [Related]
17. Rate and predictors of non-response to first-line antipsychotic treatment in first-episode schizophrenia.
Chiliza B; Asmal L; Kilian S; Phahladira L; Emsley R
Hum Psychopharmacol; 2015 May; 30(3):173-82. PubMed ID: 25758549
[TBL] [Abstract][Full Text] [Related]
18. Antipsychotic polypharmacy: do benefits justify the risks?
Tapp AM; Wood AE; Kilzieh N; Kennedy A; Raskind MA
Ann Pharmacother; 2005 Oct; 39(10):1759-60. PubMed ID: 16144885
[No Abstract] [Full Text] [Related]
19. [For: is monotherapy the gold standard of psychopharmacology?].
Fehr C
Psychiatr Prax; 2006 Jul; 33(5):207-8. PubMed ID: 16802258
[No Abstract] [Full Text] [Related]
20. The art of rational neuroleptic therapy.
Ayd FJ
Isr J Psychiatry Relat Sci; 1983; 20(4):292-8. PubMed ID: 6147324
[No Abstract] [Full Text] [Related]
[Next] [New Search]
